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Abstract
Background Substantial increases in dietary sugar intake
together with the increasing prevalence of obesity
worldwide, as well as the parallels found between sugar
overconsumption and drug abuse, have motivated research
on the adverse effects of sugars on health and eating
behaviour. Given that the gut–brain axis depends on
multiple interactions between peripheral and central sig-
nals, and because these signals are interdependent, it is
crucial to have a holistic view about dietary sugar effects
on health.
Methods Recent data on the effects of dietary sugars (i.e.
sucrose, glucose, and fructose) at both peripheral and
central levels and their interactions will be critically dis-
cussed in order to improve our understanding of the effects
of sugars on health and diseases. This will contribute to the
development of more efficient strategies for the prevention
and treatment for obesity and associated co-morbidities.
Results This review highlights opposing effects of glu-
cose and fructose on metabolism and eating behaviour.
Peripheral glucose and fructose sensing may influence
eating behaviour by sweet-tasting mechanisms in the
mouth and gut, and by glucose-sensing mechanisms in the
gut. Glucose may impact brain reward regions and eating
behaviour directly by crossing the blood–brain barrier, and
indirectly by peripheral neural input and by oral and
intestinal sweet taste/sugar-sensing mechanisms, whereas
those promoted by fructose orally ingested seem to rely
only on these indirect mechanisms.
Conclusions Given the discrepancies between studies
regarding the metabolic effects of sugars, more studies
using physiological experimental conditions and in animal
models closer to humans are needed. Additional studies
directly comparing the effects of sucrose, glucose, and
fructose should be performed to elucidate possible differ-
ences between these sugars on the reward circuitry.
Keywords Dietary sugars  Gut–brain axis 
Sugar sensing  Eating behaviour  Reward circuitry
Introduction
Dietary sugar intake, in the form of sucrose or high-fruc-
tose corn syrup (HFCS), has dramatically increased and
correlates with a rise in obesity, metabolic syndrome, and
diabetes [1]. Because a broad range of physiological,
behavioural, and neurological variables influences food
choices and eating behaviour, it is difficult to understand
the mechanisms of eating behaviour and their alterations.
The hedonic value of highly palatable foods and their wide
availability can override the physiological mechanisms
related to energy homeostasis [2, 3]. The hedonic reward
value of food is closely linked to the sensory perception of
food (including food taste, odour, and texture) and refers to
the driving force behind the motivation to eat. The nutrient
detection by the gut is mainly controlled by enteroendo-
crine (EE) cells and might activate a cascade of physio-
logical phenomena, including endocrine regulations (e.g.
insulin, leptin, glucagon-like peptide-1 or GLP-1, secre-
tion), inhibition of gastric emptying, inhibition of food
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intake [4], stimulation of intake [5] as well as psycho-
behavioural responses [6].
Dietary sugar overconsumption might provoke delete-
rious effects at both central and peripheral levels, including
alterations in (i) the regulation of secretion of satiety
peptides and neuropeptides [7, 8]; (ii) gut permeability
leading to low-grade inflammation and liver disease [9];
(iii) blood–brain barrier (BBB) permeability [9]; (iv) the
endocannabinoid [10], opioid [8], and mesolimbic dopa-
minergic systems, as well as (v) brain structures involved
in reward processing [11]. Both drugs and food have
powerful reinforcing effects partly mediated by dopamine
increases in the limbic system that, under certain circum-
stances or in vulnerable individuals, could overwhelm the
brain’s homeostatic control mechanisms [11], but the
plausibility of sugar addiction and its role in obesity and
eating disorders in humans is still a subject of controversy
[12].
Much of the research on the effects of dietary sugars
on health has recently focused on fructose, given the
striking parallel increases in obesity and in fructose intake
over the past decades [13]. These studies have found
important fructose-induced health disturbances that are
different from those provoked by glucose or sucrose.
Most of fructose intake in diets originates from sucrose
(containing 50 % fructose and 50 % glucose) and soft
drinks containing high-fructose corn syrup (HFCS) (range
47–65 % fructose, and 53–35 % glucose) [14]. An esti-
mate of the consumption of HFCS from beverages indi-
cates a daily range between 132 and 316 kcal for
Americans aged over 2 years [13], and patients with non-
alcoholic fatty liver disease (NAFLD) consume twofold
more calories from HFCS from beverages than healthy
patients (365 vs. 170 kcal/day) [15]. In the United States,
average fructose consumption from sugar-sweetened
beverages has increased from 37 to 49 g/day during the
last 30 years (?0.4 % per year) [16]. The increase in
fructose consumption is synonymous with increased
energy intake. Thus, it is not clear whether the fructose-
induced metabolic disturbances observed in human and
animal studies are due to fructose itself or the associated
increase in energy intake. Moreover, since fructose and
glucose intake may vary simultaneously, this raises the
consideration that other dietary sugars (e.g. sucrose and
glucose) might also contribute to the development of
obesity and associated co-morbidities.
In fact, there are controversial findings on metabolic
effects between the different sugars (i.e. glucose, fructose,
and sucrose). While some studies have disclosed signifi-
cant differences between these sugars, other studies have
found small or no difference. For example, in overweight
or obese humans, intake of a fructose-sweetened beverage
led to a significant increase in visceral adipose tissue,
hepatic de novo lipogenesis, and postprandial triglycerides
compared to subjects offered a glucose-sweetened bever-
age [17]. In lean and obese subjects, de novo lipogenesis
increased to the same extent after overfeeding with glu-
cose and sucrose [18]. Both high-glucose and high-fruc-
tose diets stimulated lipogenic gene expression in rodents
[19].
Most of the studies on the effects of sugars on health
and disease, at both peripheral and central levels, have
been performed in rodents, and studies are missing in
humans or other animal models closer to humans, such
as the pig model. Given that human studies are limited
due to ethical considerations, future studies should
privilege the use of animal models that closely resembles
humans.
On the other hand, there is an impressive number of
studies available concerning the effects of dietary sugars,
using different experimental paradigms, with different
approaches, animal models, oral intake doses, in the form
of sugar solutions or added in the diet, or peripheral or
central administrations. Therefore, it becomes extremely
difficult to interpret and find a definite conclusion on these
effects. In this context, we considered essential to gather all
the information available to give a global view of the
current research in this domain, in order to highlight the
need to reformulate the questions and approach to these
questions, under similar conditions between studies, and
using integrated approaches, from the molecular to the
behavioural level.
The main goal of this review was to provide an overview
of the impact of different dietary sugars on peripheral and
central functions. It will gather (i) results from studies
regarding the effects of sucrose, glucose, and/or fructose on
metabolism, eating behaviour, and brain responses; (ii)
current available data comparing the effects of these sug-
ars, at both peripheral and central levels. It will also pro-
pose some clues and hypotheses for future research
perspectives regarding the effects of these sugars, with
special focus on fructose and glucose.
The pig model in biomedical research
Even though this review synthetises data from different
animal models and humans, we wanted to dedicate a short
section to the presentation of the pig model, which is of
particular interest in nutrition and neurosciences. Pigs
have emerged as an ideal model for nutritional and bio-
medical research because of their anatomical and physi-
ological similarities to humans [20–22], as well as blood
chemical and biochemical characteristics, plasma hor-
mone levels, and energy metabolism [23]. Pigs are able to
distinguish the palatability of different diets, and they
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have a high innate preference for sweet taste [24] and a
strong appetite for sugar solutions [25]. The digestive
system of pigs has anatomical differences with that of
humans; however, the physiology of digestion is essen-
tially similar. Swine are true omnivores. In spite of the
anatomical differences, the pig has been used extensively
as a model of digestion in connection with nutrition (and
determination of food value) of the pig and for studying
human digestive phenomena. The metabolic functions,
intestinal transit times, and characteristics of nutrients
absorption have made them useful in basic nutritional
research. Other specific functional characteristics of swine
that relate directly to humans include ion transport and
motility, neonatal development of the gastrointestinal
tract, and splanchnic blood flow characteristics. Like
humans, these physiological characteristics of the gastro-
intestinal tract are probably due to the omnivorous diet
they consume, unlike that of carnivores, ruminants, rab-
bits, and rodents [26]. Similar to carbohydrate (sucrose
and starch) digestion in humans [27], it was shown in
non-anaesthetised mature pigs following the intake of
different sugar-containing meals (with glucose, sucrose,
lactose, or maize starch) that the absorption pattern was
different for each sugar. The kinetics of appearance of
glucose and of sucrose hydrolysis products in the portal
blood were faster for glucose and sucrose than for sugars
resulting from maize starch hydrolysis [23].
Recent studies have shown the convenience for the use
of pig model in brain imaging, behavioural, and physi-
ological effects of obesity induced by highly palatable
diets [20, 22, 28, 29]. Compared to the rodent brain, the
pig brain more closely resembles the human brain in
terms of anatomy and biochemistry, which associates the
pig with a higher translational value. Several brain dis-
orders have been fully or partially modelled in the pig,
and this has further spurred an interest in having access
to behavioural tasks for pigs and in particular to cogni-
tive tasks. Cognitive testing of pigs has been conducted
for several years in animal science, but it has only
recently received interest in the wider neuroscience
community. Several behavioural tasks have successfully
been adapted to the pig, and valuable results have been
produced [30].
Aside of having similar brain structures to humans, the
pig might develop metabolic disorders observed in humans
(excessive fat deposition, diabetes, atherosclerosis, hyper-
tension) [31]. Taken together, these data position the pig
model as a valuable model for biomedical studies in
nutrition and neuroscience. Therefore, future studies on the
effects of dietary sugars on health and disease should
favour the use of the pig model in order to extrapolate data
to humans and propose modifications in the nutritional
recommendations for humans.
Effects of dietary sugars on gut microbiota, intestinal
barrier, and liver
Gut microbiota operates like a metabolic organ, influencing
nutrient availability and uptake, energy homeostasis, and
the control of body weight. Diet composition may strongly
influence changes in the microbiota, which in turn, when
subjected to deleterious nutritional environment, might
affect intestinal permeability and result in low-grade
inflammation, obesity, and associated chronic metabolic
diseases such as NAFLD, dyslipidaemia, and insulin
resistance [9, 32].
Increases in gut permeability, low-grade endotoxemia
(provoked by increased plasma lipopolysaccharides—
LPS), and hepatic lipid accumulation have been reported in
animal models of obesity induced by high-fat or high-
fructose diets. A high-fructose diet has been associated
with hepatic and extra-hepatic insulin resistance and
obesity-related metabolic disturbances through a mecha-
nism implicating gut microbiota and its effects on intestinal
permeability [9].
Liver disease and inflammation
The hepatic manifestation of the metabolic syndrome is
NAFLD, starting from simple steatosis and ending as liver
cirrhosis. Dietary sugar intake might participate to NAFLD
pathogenic history, and the type of sugar (e.g. fructose)
may affect the development of the disease [33]. Consistent
evidence has demonstrated the implication of fructose or
HFCS in the development of NAFLD in several animal
models [17, 33–38]. The effects of dietary sugars, espe-
cially fructose, on the development of hepatic steatosis,
liver damage, and other features of the metabolic syndrome
found in several animal models are presented in Table 1.
It seems that HFCS or fructose exposure is able to
induce hepatic steatosis, liver dysfunction, hepatic fibrosis
as well as several features of the metabolic syndrome and
inflammation in rodents and cats (e.g. [39–44]). However,
in other species such as pigs or in humans, this concept
remains incompletely clear. Data obtained from humans
[45] and Osabaw minipigs [31] suggested that it is the
association between high-fructose intake with other com-
ponents in the diet, such as glucose, sucrose, fat, and
cholesterol, responsible for the development of the meta-
bolic syndrome and liver steatosis, rather than high-fruc-
tose intake itself. The approach used in several human
studies where fructose daily intake pattern is assessed in
patients with previously established hepatic steatosis [33,
46, 47] is not the best way to evaluate fructose as a risk
factor for NAFLD. This question should be addressed in a
more controlled experimental paradigm where dietary
intake is closely monitored. To our knowledge, one of the

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 Eur J Nutr (2015) 54:1–24
123
few human studies that has assessed the effect of glucose-
or fructose-sweetened beverages on the development of
hepatic de novo lipogenesis under controlled conditions is
the one performed by Stanhope et al. [17]. However, this
study did not confirm the presence of hepatic steatosis
using standard diagnostic methods such as MRI, CT scan,
or liver biopsy. Thus, studies in humans are needed to
investigate the effects of dietary sugars on the development
of hepatic steatosis under controlled experimental
conditions.
Taken together, studies with rodents and cats suggest
that fructose induces liver damage, in part through mech-
anisms involving intestinal bacterial overgrowth, increased
intestinal permeability, inflammation, and metabolic
endotoxemia. However, underlying mechanisms explaining
how fructose leads to bacterial overgrowth, inflammation,
and increases in intestinal permeability remain poorly
understood. Additional studies are necessary to further
explore this hypothesis in humans. Since it is difficult to
achieve controlled experimental conditions in humans, for
ethical reasons, studies in animal models closer to humans,
e.g. pigs [20, 28, 31], are a valuable approach that allows
close monitoring of dietary interventions. If similar
mechanisms occur in humans and pigs, novel strategies
including low-fructose diets might be considered for the
prevention/management of NAFLD. However, there seems
to be substantial differences between rodents or cats and
humans or pig studies. Thus, in the absence of clear evi-
dence for a detrimental role for fructose, there is no justi-
fication for replacing it with other dietary sugars such as
glucose or sucrose in human diets for the prevention of
hepatic steatosis.
Effects of dietary sugars on the regulation of food
intake
The regulation of food intake and energy homeostasis is
achieved by a complex network communication between
the periphery (e.g. gut, liver, stomach, pancreas, and adi-
pose tissue) and the brain. This regulation has been
extensively reviewed already (e.g. [48–51]). The different
molecular structures of dietary sugars might result in dif-
ferent gastrointestinal peptide secretion profiles, leading to
different metabolic and endocrine effects at both peripheral
(e.g. gut and liver) and central (e.g. hypothalamus) levels
[52–54]. It has been shown that fructose, compared to
glucose intake, produces smaller increases in plasma glu-
cose and circulating satiety hormones, i.e. insulin, leptin,
glucagon-like peptide-1 (GLP-1), peptide tyrosine tyrosine
(PYY), and attenuates postprandial suppression of ghrelin
[37, 55–59]. This suggested an endocrine mechanism by
which fructose might induce a positive energy balance and
weight gain. A possible explanation of smaller increases in
satiety hormones by fructose could be the lower expression
of GLUT5 in b-cells [60] or lower absorption rates in the
intestine [61]. In addition, it was found that central
administration of fructose provokes feeding in rodents,
whereas centrally administered glucose promotes satiety
[54, 62]. These data together with parallel increases
between fructose intake and obesity development [13] have
led to the ‘fructose hypothesis’ which postulates that
fructose, compared to glucose, may stimulate food-seeking
behaviour, food intake, and body weight gain. However,
the proposed effect of fructose on the induction of feeding
is the subject of debate since this concept has not been
replicated in rodents, and there is little evidence linking
these phenomena in humans [56, 58, 59, 63, 64]. The few
studies linking fructose consumption with increased body
weight compared fructose versus an artificial sweetener
[65], evaluated 60-g fructose supplementation but did not
compare it versus another sugar [66], or used higher doses
of fructose compared sucrose [67]. Even others found no
substantial differences in endocrine and metabolic effects
after consumption of sugar-sweetened beverages with
HFCS, sucrose, fructose, and glucose in humans [68] or in
body weight and food intake [69] or found greater increase
in body adiposity with sucrose than with fructose solutions
[70]. Moreover, it appears that fructose orally ingested may
cross the BBB to a small extent compared to glucose,
which may have two opposite implications: 1) the limited
fructose access to glucose-sensing neurons could contribute
to the deregulation of food intake and energy balance, or 2)
fructose might have no effect at all on appetite regulation
due to the lack of fructose transport to the brain. These
hypotheses need to be investigated and clarified in future
studies. The purpose of this section was to present available
data on the main enteric and cephalic detection processes
of dietary sugars, in association with satiety peptides,
neuropeptides secretion, and neuronal activity, and to dis-
cuss their effects on food intake.
Oral and enteric detection of dietary sugars: sweet taste
receptors and sugar transporters
Peripheral sweet taste and sugar detectors are key regula-
tors of feeding behaviour and energy homeostasis. Taste-
signalling mechanisms identified in the oral epithelium also
operate in the gut and play a role in both sugar detection
and regulation of intestinal and pancreatic hormone
secretion [71]. There are two main groups of sugar detec-
tors: members of the G-protein-coupled receptors (GPCR)
family, and sugar transporters (e.g. GLUT2, GLUT5,
sodium-dependent glucose co-transporter 1 (SGLT1), and
GLUT8). Enteroendocrine cells directly sense sugars via
GPCR, including the sweet taste receptors of type 1, T1R.
Eur J Nutr (2015) 54:1–24 5
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These receptors have also been implicated in sweet taste
preferences [72].
The T1R2/T1R3 heterodimers form sweet taste recep-
tors that recognise several natural and synthetic sweeteners.
The initial step in taste recognition occurs on the apical
surface of taste receptor cells, within taste buds of the
tongue and palate [73]. The regulation of taste sensitivity
by appetite peptides at the level of taste bud cells in the
tongue as well as in enteroendocrine cells of the taste
epithelium may be important in the control of eating
behaviour and the regulation of energy homeostasis [74].
However, this concept remains unclear since it was found
that knockout (KO) mice (P2X2/P2X3) with adenosine
triphosphate taste cell signalling deficits show relatively
normal food intake and body weight. They also develop
strong preferences for non-taste nutrients by the post-oral
actions of these nutrients [75]. Furthermore, much of the
research on appetite peptides and taste detection in the
mouth has been performed at the cell/neuron level; how-
ever, little empirical evidence exists to date for these
peptides impacting taste function at the level of the mouth.
Therefore, more studies should be performed in large
animal models to clarify these concepts.
Appetite regulatory peptides, such as leptin, endocan-
nabinoids, GLP-1, glucagon, oxytocin, insulin, cholecys-
tokinin (CCK), neuropeptide Y (NPY), and vasoactive
intestinal peptide (VIP), modulate taste sensitivity at the
level of oral sweet taste cells [74]. Leptin selectively
suppressed sweet taste responses of cells isolated from
circumvallate papillae from non-diabetic mice, but not in
diabetic db/db mice. This indicated that the effect of leptin
on sweet taste sensitivity is mediated by the leptin receptor
expressed in these cells [76]. The T1R3 subunit is co-
expressed with the leptin receptor in both fungiform and
circumvallate taste bud cells, and leptin suppresses sweet
taste sensitivity in mice by affecting responsiveness of
T1R3-expressing taste cells via the leptin receptor.
Therefore, leptin may play an important role in the regu-
lation of sweet taste sensitivity in the tongue, besides its
central actions on food intake [77].
Co-expression of GLP-1 with taste-signalling elements
such as T1R2, T1R3, and a-gustducin, a Gai family
member associated with taste perception, was found in
human intestinal endocrine L cells [78]. These taste-sig-
nalling elements mediate the glucose-dependent secretion
of GLP-1 and maintain or enhance sweet taste sensitivity
via paracrine action [78]. In addition to its intestinal
expression, GLP-1 was also found to be expressed in taste
cells in mouse circumvallate papillae taste buds; it was co-
expressed with a-gustducin and T1R3-expressing sweet
taste cells in mouse taste buds, and it was produced in taste
buds from lingual extracts in its active form [79]. In con-
trast to its presence in blood and ileum [80], dipeptidyl
peptidase 4 was not found to be expressed in taste buds,
suggesting that the half-life of GLP-1 in taste tissue should
be high, ensuring sufficient concentrations within the taste
bud to stimulate the GLP-1 receptor [79].
HEK-293 cells expressing Ga15 (a phospholipase
C-linked G-protein), cotransfected with human and rat
T1R2/T1R3, respond to all sweet taste stimuli: sucrose,
fructose, galactose, glucose, lactose, and maltose [81]. In
the rat, however, the relative lack of T1R2 expression in
taste bud cells of the fungiform papillae is consistent with
the relative low response to sucrose recorded at the level of
the chorda tympani nerve [82] The activation of T1R1/
T1R3 and T1R2/T1R3 in rat small intestine by glutamate,
glucose, and artificial sweeteners increases the apical
expression of GLUT2 and sugar absorption [83, 84]. Given
this effect of sweet taste per se to activate T1R2/T1R3 and
sugar absorption, it would have been expected that artificial
sweeteners might also slow gastric emptying. However,
intragastric or intestinal administration of equisweet solu-
tions with artificial sweeteners and/or fructose did not
modify glucose absorption rates, plasma glucose, incretin
levels, or gastric emptying in humans [85–87] or rodents
[88] as a glucose solution did. Collectively, these findings
did not support the concept that the sweet taste per se is the
principal detection mechanism, responsible for the regu-
lation of gastric emptying, glucose absorption, or incretin
release. Therefore, these data are in contrast to previously
reported parallels between nutrient-sensing pathways in the
oral cavity and gut [89]. It seems that artificial sweeteners
may influence the expression of sugar transporters such as
GLUT2 [83, 84] and SGLT1 [90], but they may not
influence other physiological functions such as gastric
emptying or glucose absorption, and their effect on incretin
release seems contradictory since some studies reported an
effect of artificial sweeteners (sucralose) on GLP-1 secre-
tion from the ileum via T1R3 activation [71], while other
studies did not find any effect of artificial sweeteners on
incretin levels in humans [85–87] or rodents [88] when
compared to glucose effects. Therefore, these data make
unclear whether sweet taste receptors are necessary in such
gastrointestinal functions.
T1R1/T1R3 and T1R2/T1R3 stimulation leads to the
activation of a-gustducin [91]. T1R3 and a-gustducin are
necessary for increased stimulation of (SGLT1) by dietary
sugars [92]. T1R3 inhibition with lactisole decreased
fructose stimulation of human SGLT1, GLUT5, and
L-pyruvate kinase mRNA expression, demonstrating the
implication of T1R3 in fructose signalling, whereas T1R3
did not control GLUT2 expression and activity [93].
In enterocytes, cell polarity may influence the regulation
of sweet taste receptor signalling. TIR2 and T1R3 are
located at the basolateral membrane of differentiated en-
terocytes. Whereas the apical supply of fructose increased
6 Eur J Nutr (2015) 54:1–24
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GLUT5 mRNA expression, the basolateral supply of sugars
increased GLUT2 expression, suggesting that sugars can
directly signal from the basolateral membrane [93].
When intestinal luminal glucose concentration is lower
than in plasma, glucose is transported by SGLT1 through
the apical membrane against the concentration gradient.
Dietary fructose is transported across the apical membrane
by the facilitative transporter GLUT5. In the basolateral
membrane, both glucose and fructose are transported by
GLUT2 [94, 95]. At high glucose or fructose concentra-
tions, when SGLT1 and GLUT5, respectively, are satu-
rated, GLUT2 translocates to the apical membrane where it
complements SGLT1 and GLUT5 transport capacities.
Apical GLUT2 participates in the energy-sensing mecha-
nism [96]. Depending on its relative abundance in the
apical and basolateral membranes, it may stimulate sugar
signals from intestinal lumen or bloodstream. Chronic
exposure to a high-sugar diet promotes increased apical
GLUT2 levels, increases glucose absorption, and excessive
postprandial excursions [94]. Insulin induces the inter-
nalisation of apical GLUT2, a process that is impaired in
insulin resistance, contributing to further glucose absorp-
tion [97]. Since GLUT2 depends on glucose transport by
SGLT1, i.e. it promotes GLUT2 upregulation [98], long-
term regulation by SGLT1 may also be reflected in changes
in apical GLUT2 [94]. In piglets fed isocaloric diets with
variable concentrations of digestible carbohydrates (i.e.
sucrose and maize starch), SGLT1 expression remains
constant after exposure to diets containing up to 40 %
digestible carbohydrate. However, after exposure of[50 %
carbohydrate diets, SGLT1 expression is markedly
increased. In contrast, under both low- and high-carbohy-
drate diets, GLUT2 is expressed on the basolateral mem-
brane of pig enterocytes. These results suggest that SGLT1
is the major route for the absorption of dietary sugars
across the luminal membrane of swine enterocytes [99].
Moreover, duodenal and jejunal infusions of glucose,
fructose, and saccharin induced up-regulation of SGLT1 in
mice apparently involving vagal afferents [90]. Altogether,
these data suggest that SGLT1 and apical GLUT2 are
potential targets for antidiabetic therapy [90, 93, 94].
Duodenal SGLT1 and GLUT5 mRNA expressions and
protein levels are substantially increased in diabetic
patients. Reduction in plasma glucose in these patients
promoted a reduction in both SGLT1 and GLUT5 levels,
suggesting that under hyperglycaemic conditions, the
absorption of sugars is enhanced [100]. Moreover, post-
prandial plasma fructose levels are increased in diabetic
patients and are associated with the prevalence of diabetic
retinopathy [101]. In contrast, in Zucker diabetic rats,
mRNA and protein levels of SGLT1, GLUT5, and GLUT2
were unchanged compared to lean controls [102]. This
suggests that the Zucker diabetic rat might not be a good
model for the study of diabetes since it does not reproduce
results observed in humans.
Consumption of a large amount of pure fructose can
exceed the capacity of intestinal fructose absorption,
resulting in diarrhoea. However, the consumption of glu-
cose along with fructose, as it is usually consumed in
beverages and with meals (e.g. when provided as sucrose),
appears to enhance fructose absorption. In addition, fruc-
tose absorption increases during sustained fructose con-
sumption, suggesting an adaptation to increased fructose
intake [37]. GLUT8, expressed only in the intracellular
compartment, potentially mediates sugar transport into or
out of intracellular organelles [103]. GLUT8 has high
affinity for glucose, whereas fructose and galactose com-
pete with glucose transport activity [97]. Its deficiency
enhances fructose uptake in cultured Caco2 human intes-
tinal epithelial cells and in jejunum isolated from mice
lacking the gene encoding GLUT8. Moreover, mice lack-
ing GLUT8 rapidly develop higher serum fructose con-
centrations after oral fructose gavage. These effects are
possibly mediated by the stabilisation of the dual-speci-
ficity glucose/fructose transporter GLUT12 [104]. These
data might lead to the speculation that this transporter
could, in part, be implicated in fructose malabsorption
previously reported when ingested at high levels in humans
[105]. Further studies are needed to investigate this
hypothesis.
Enteric dietary sugar sensing and the regulation
of peptides secretion
The glucose-dependent secretion of GLP-1 plays a critical
role in the regulation of glucose homeostasis. It was shown
that T1R3, but not T1R2, affects both incretin secretion
from the intestine and insulin secretion from the pancreas
[71]. Exposure to glucose, fructose, and sucralose induced
GLP-1 secretion from the ileum of wild-type (T1R3?/?)
but not from T1R3 null mice (T1R3-/-). T1R2-/- mice
showed normal glycaemic control and partial small intes-
tine glucose-stimulated GLP-1 secretion, suggesting that
T1R3 can mediate glucose-stimulated GLP-1 secretion
without T1R2 [71]. GLP-2 promotes GLUT2 insertion in
the apical membrane, stimulating jejunal fructose transport
[106]. SGLT1 and SGLT3 may also be involved in enteric
sugar-sensing and hormonal secretion stimulation [107].
SGLT1 triggers glucose-induced secretion of gastrointes-
tinal polypeptide (GIP) from K-cells in the duodenum and
jejunum [98]. This in turn stimulates the release of GLP-1
and GLP-2 from L cells located in the ileum [107, 108].
Some evidence has revealed an anorexigenic effect of
glucose and an orexigenic effect of fructose through dif-
ferent secretory profile of appetite peptides. For example,
glucose and, to a lesser extent, galactose, but not fructose,
Eur J Nutr (2015) 54:1–24 7
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mannose, or sorbitol, stimulated the release of GIP [52].
Glucose intragastrically infused or orally ingested induced
an increase in plasma glucose levels, stimulated insulin,
leptin, GLP-1 and peptide tyrosine–tyrosine (PYY) secre-
tion, and reduced ghrelin secretion, while fructose did not
substantially affect these hormones [37, 57–59]. However,
in one of these studies [58], the amounts of intragastric
load of glucose and fructose were different (50 and 25 g/
250 mL, respectively), which might have contributed to the
observed differences [58].
A possible explanation for the lack of effects of fructose
on insulin secretion may be related to lower intestinal
mRNA and protein GLUT5 levels compared to GLUT2
levels [109], with the subsequent lower fructose transport
compared to glucose. In addition, it was previously shown
that glucose absorption rate was higher than that of fructose
in Yucatan minipigs [61]. A substantial portion (12 %) of
ingested fructose is metabolised to lactate by the gut during
absorption, while only 2 % of glucose ingested is metab-
olised in the gut and almost all of the absorbed glucose
appears in the portal vein as glucose. In concordance with
lower fructose absorption rates compared to glucose,
insulin concentrations were 7.5-fold above basal conditions
following glucose intake, compared to threefold following
fructose intake [61]. Another possible explanation for the
lack of effects of fructose on insulin secretion is the low
level of expression of the GLUT5 fructose transporter in b-
cells [60]. Taking together these data, i.e. lower expression
levels of GLUT5 than GLUT2 in the intestine, lower rate
of fructose transport compared to glucose, partial intestinal
fructose, but not glucose, metabolism, and the low level of
GLUT5 expression in b-cells could explain in part the
lower increases in other gut peptides, besides insulin,
induced by fructose ingestion, compared to glucose. Fur-
ther studies are needed to confirm this concept. In this
context, since insulin and leptin function as key signals in
the central nervous system through the modulation of
hypothalamic neuropeptides for the long-term regulation of
energy balance, chronic fructose intake could lead to
increased calorie intake, thereby contributing to weight
gain and obesity [110].
Cephalic detection of dietary sugars in the regulation
of peptide secretion and neuronal activity
Hunger is regulated by the hypothalamus and the dorsal
vagal complex in conjunction with an integrated network
of limbic brain structures such as the striatum, orbitofrontal
cortex, amygdala and insula, which control motivation-
reward systems associated with the hedonic drive to eat
[97]. The arcuate nucleus of the hypothalamus is an inte-
grator of hormonal and nutrient information to regulate
both energy and glucose homeostasis. Brain cells are
provided with mechanisms that sense energy availability in
the extracellular space, such as an increase in adenosine
monophosphate kinase (AMPK) activity in response to an
increase in AMP-to-ATP ratio [50].
Glucose-sensing neurons are located in brain areas
involved in the control of neuroendocrine function, nutrient
metabolism, and energy homeostasis (e.g. hypothalamic
arcuate nucleus and the dorsal vagal complex) and also
receive direct and indirect neural input from the periphery
and from other brain areas that carry information about the
characteristics of the ingested nutrients [50]. Glucose-
sensing neurons express receptors for and respond to
peripheral hormones such as leptin and insulin that convey
signals relating to carbohydrate and fat stores. These hor-
mones as well as metabolic substances are transported
across the BBB but can also freely diffuse from capillaries
to the adjacent median eminence. Anabolic arcuate NPY/
agouti-related protein (AgRP) and catabolic proopiomela-
nocortin (POMC) neurons are metabolic sensors with
important roles as regulators of energy homeostasis [111].
Arcuate NPY/AgRP neurons are inhibited by insulin and
leptin and, when activated, stimulate food intake (orexi-
genic), whereas POMC neurons reduce food intake
(anorexigenic) and are stimulated by insulin and leptin.
Both neuronal subsets project to secondary order neurons
located adjacent to hypothalamic areas including the
paraventricular nucleus, where anorexigenic neurons are
concentrated, and the lateral hypothalamic area, which
contains orexigenic neurons. NPY/AgRP neurons also
inhibit POMC neurons via synaptic release of the inhibi-
tory transmitter, c-aminobutyric acid [112]. Through
smaller increases in insulin and leptin secretion induced by
fructose intake, compared to glucose [55, 59], fructose-
containing diets may lead to a lower inhibitory effect of
orexigenic neurons NPY/AgRP, as well as a reduced
reward value from food [113]. This hypothesis should be
investigated in future studies.
Differential fuel utilisation responsible for the distinct
responses of the NPY/AgRP and POMC neurons to meta-
bolic signals has been characterised, whereas POMC neu-
rons utilise glucose as the main fuel, NPY/AgRP neurons
do not use glucose, but free fatty acids instead. This dif-
ferential fuel utilisation implies two distinct and competi-
tive mechanisms, glycolysis and ß-oxidation, in these
neuronal populations. When glycolysis is elevated, ß-oxi-
dation is inhibited and vice versa. Thus, glucose enhances
POMC and reduces NPY/AgRP neuronal activity. The by-
products of substrate oxidation are reactive oxygen species
(ROS) that have a crucial role in the acute and the long-
term regulation of feeding, satiety, and associated meta-
bolic changes (i.e. glucose and fatty acid homeostasis).
Mitochondrial ROS (mROS) is a necessary signal to ini-
tiate the response to glucose sensing. A finely controlled
8 Eur J Nutr (2015) 54:1–24
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mROS production might be considered as an essential
physiological messenger in metabolic-sensitive cells [114,
115]. Alteration of the hypothalamic glucose-sensing
mechanism induced dramatic effects on energy balance
correlated to abnormal redox signalling originated from
mitochondrial dysfunction [116]. During negative energy
balance, NPY/AgRP neurons utilise free fatty acids as fuel,
but ROS levels are not increased in these cells despite
increased firing and substrate utilisation. In contrast, during
positive energy balance, when glucose-utilising POMC
neurons are firing at high levels, ROS accumulate in these
POMC cells because they do not need to be buffered [50].
Sustained ROS levels in POMC neurons seem to favour
satiety. The fact that satiety is associated with the highest
levels of ROS production in the POMC neurons indicates
that these cells are more exposed to ROS-induced damage
than NPY/AgRP neurons, which do not produce elevated
ROS levels even if highly active. Thus, it seems plausible
that POMC neurons are more exposed to elevated firing
(positive energy balance) over time, thus leading to POMC
system impairment. In contrast, since NPY/AgRP neurons
are inherently able to buffer ROS, their increased activity
during negative energy balance is not associated with ROS-
induced degeneration [50].
The role of AMPK in the regulation of food intake has
been well demonstrated. Regulatory mechanisms of food
intake controlled by central AMPK activity in response to
an i.c.v. injection of glucose and fructose are presented in
Fig. 1. These data suggested an anorexigenic effect of i.c.v.
glucose injection through inactivation of AMPK, an
increase in malonyl CoA, and in anorexigenic neuropep-
tides mRNA levels in the hypothalamus, whereas i.c.v.
fructose injection resulted in the inverse effects [50, 54,
117, 118] (see Fig. 1). However, whether fructose orally
ingested can also produce these effects than when admin-
istered i.p. or i.c.v. remains to be investigated.
Another potential mechanism for the fructose effects on
food intake might be through the nuclear receptors liver X
receptor (LXR) a and b. These receptors have been pre-
viously implicated in the regulation of carbohydrate and
lipid metabolism [119] and were shown to be expressed in
the hypothalamus and implicated in the regulation of food
intake [120]. Free access to a diet-containing 10 % fructose
for 6 weeks in glucose-intolerant rats induced a decrease in
LXRb and an increase in LXRa in the hypothalamus, but
not in the hippocampus, cerebellum, or neocortex. It is
possible that the specific hypothalamic increase in LXRa
by fructose may trigger neurochemical and neurophysio-
logical responses for the control of food intake and energy
expenditure [120]. But further studies are needed to
investigate this hypothesis.
Circulating fructose levels could possibly promote
central effects in humans even if hepatic clearance of
fructose is extremely efficient, given the following obser-
vations: (i) the presence of GLUT5 in the BBB and ke-
tohexokinase mRNA, the necessary cellular machinery for
fructose metabolism [57]; (ii) fructose administered i.p. can
cross the BBB and trigger neuronal activation in rodents
[57]; (iii) fructose administrated i.p. can be metabolised to
lactate in the hypothalamus [121]. These data suggested the
capacity of fructose to cross the BBB into the hypothala-
mus, where it could be metabolised and used as an energy
source. Thus, consumption of high-fructose diets might
probably have a direct effect on the brain, but no study has
clearly proven this concept yet. While it is well established
that glucose orally ingested undergoes facilitated transport
across the BBB [122], the demonstration that fructose
orally ingested can cross the BBB is still missing. Another
question is how changes in feeding behaviour associated
with glucose- and fructose-induced activation of brain
regions observed in animals could be extrapolated to
humans, especially when most of the studies investigating
these effects have been performed on rodents.
Dietary sugar sensing on brain activation and eating
behaviour
New technologies are available to facilitate the translation
of animal to human studies and help understanding of brain
functions. One such technique is the single-photon emis-
sion computed tomography (SPECT) that provides a way to
compare brain circuits implicated in the processing of oral
and/or visceral (e.g. duodenal or portal) sugar signals.
Boubaker et al. [123] evaluated brain activity in a juvenile
pig model using SPECT following visceral nutritional
stimulation. The authors found that both duodenal and
portal glucose infusions activated the dorsolateral pre-
frontal cortex and primary somatosensory cortex. However,
only duodenal glucose infusion induced the activation of
the prepyriform area, orbitofrontal cortex, caudate and
putamen, and the deactivation of the anterior prefrontal
cortex and anterior entorhinal cortex, whereas only portal
glucose infusion induced the activation of the insular cor-
tex. These results indicated that duodenal and portal glu-
cose infusions modulate differentially the activity of brain
areas implicated in the regulation of eating behaviour,
which probably explains the decrease in food intake after
both stimulations [123]. Another SPECT study in pigs
(Clouard et al., 2013, unpublished data) demonstrated that
combined oral and duodenal sucrose sensing induced
activation of brain regions involved in memory, reward
processes, and hedonic identification of sensory stimuli
(i.e. amygdala, dorsal striatum: caudate and putamen, and
the anterior prefrontal cortex), whereas oral or duodenal
sucrose sensing individually administered did not. These
findings suggested that (1) the concordance between oral
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and visceral signals (sweet taste and calories) during sugar
sensing is necessary for the onset of responses in these
brain structures, or (2) the synergy between oral and vis-
ceral signals during sugar sensing is required to obtain a
signal that is strong enough to trigger brain responses in
these structures (Clouard, et al., 2013, unpublished data).
Positron emission tomography (PET) studies with
18-fluorodeoxyglucose (18-FDG) to measure brain glucose
metabolism in normal-weight individuals reported that
exposure to food cues increased metabolic activity in the
orbitofrontal cortex, similar to that observed in cocaine-
addicted subjects, which was an effect associated with the
perception of hunger and the desire for food [124]. Func-
tional magnetic resonance imaging (fMRI) is another
technique that provides a non-invasive way to assess the
effects of glucose and fructose intake, as well as of obesity,
on regional cerebral blood flow (abbreviated rCBF and
estimated via the blood–oxygen-level-dependent or BOLD
signal) [97]. Previous studies have explored the temporal
response to glucose intake or infusion using fMRI and
found suppression of hypothalamic BOLD signalling after
the administration of glucose to rats and humans. Obese
subjects presented diminished attenuation of the BOLD
signal in response to glucose ingestion compared with lean
subjects, and patients with type 2 diabetes did not show any
hypothalamic signal changes compared with non-diabetic
patients [125]. This might suggest a reduced neuronal
activation in obese relative to lean subjects, which might
translate in no suppression of appetite and less rewarding
signals from glucose intake leading to overeating. Cortical
responses to sugars in healthy subjects as assessed by fMRI
appear to be opposite between glucose and fructose infu-
sion: increased and decreased cortical activation, respec-
tively [126]. The suppressive effect of fructose on cortical
BOLD signal occurred despite the fact that cortical-specific
receptors (GLUT5) are present in low concentrations
throughout the brain, where the glucose transporter GLUT3
predominates. Whether this cortical response to fructose is
due to effects mediated by GLUT2 and GLUT5 carriers in
the BBB or in local glial cells, due to increased osmolality,
or is the indirect result of changes in the levels of periph-
eral neural input or metabolic intermediaries is yet to be
understood. However, the overall observations suggest a
major implication of fructose on changes in brain activity
Fig. 1 Effects of an i.c.v. injection of fructose or glucose on central
neuropeptides and appetite. Glucose transport is facilitated by the
Na? gradient. Fructose transport across the membrane by GLUT5
does not need ATP. Fructose bypasses the rate-limiting step in
glycolysis, which generates a decrease in AMP/ATP ratio, the
phosphorylation and activation of AMPK (the cell sensor of AMP/
ATP ratio) in the liver [180], and in hypothalamic neurons [50, 54].
This stimulates corticosterone secretion, activating glucocorticoid
receptors followed by activation of phosphoenol pyruvate carboxy-
kinase (PEPCK) and gluconeogenesis [181]. The activation of
PEPCK induced by fructose was prevented by RU486, a glucocor-
ticoid receptor antagonist [118]. Intracerebroventricular (i.c.v) injec-
tion of the GLP-1 receptor (GLP-1R) agonist exendin-4 (Ex-4),
suppressed AMPK activity in hypothalamic cells and food intake;
i.c.v fructose attenuated the anorectic effect of Ex-4, suggesting a
mechanism for the increased food intake by fructose via impairment
of central GLP-1R action [117]. Glucose injected i.c.v. increased
ATP/AMP ratio, activated AMPK, acetyl-CoA carboxylase (ACC)
and malonyl CoA, leading to decreased mRNA levels of orexigenic
neuropeptides NPY and agouti-related protein (AgRP), while acti-
vating the expression of the anorexigenic peptides cocaine–amphet-
amine-related transcript (CART) and proopiomelanocortin (POMC).
These signals suppress food intake and increase energy expenditure.
Fructose i.c.v injected exerts an orexigenic effect by lowering
malonyl CoA mRNA levels [54]
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similar to those observed with addictive drugs, which may
lead to an altered reward response to palatable food [126].
In contrast to the effects of sugars in cortical activation,
their effects in other brain regions involved in food intake
control, i.e. hypothalamus, appear to be opposite. Another
fMRI study in humans showed that glucose, but not fruc-
tose intake, induced a marked reduction in hypothalamic
BOLD signal, as well as a reduction in CBF within the
thalamus, insula, anterior cingulate, striatum, and hypo-
thalamus, i.e. brain regions that act together to sense the
metabolic state of an individual and drive motivation and
reward. Moreover, fructose produced a transient increase in
hypothalamic activity and reduced CBF in the hippocam-
pus, a region implicated not only in memory but also
influencing emotional responses to food intake. These
findings suggest that ingestion of glucose, but not fructose,
initiates a coordinated response between the homeostatic
and striatal networks that regulate eating behaviour [57]. In
line with these data, ingestion of glucose but not fructose
produced increased ratings of satiety and fullness [57].
What are the underlying mechanisms of these effects of
fructose on CBF changes is a remaining question since no
study has clearly demonstrated the capacity of fructose
orally ingested to cross the BBB.
Figures 2 and 3 represent hypothetical and controversial
models summarising the findings that support the ‘fructose
hypothesis’ which postulates an orexigenic and less
rewarding effect of fructose intake, compared to glucose. It
presents the underlying molecular mechanisms throughout
the gut–brain communication supporting this hypothesis.
Dietary sugars and the mesolimbic dopamine system
The mesolimbic dopamine (DA) system plays a critical
role in the reinforcing effects of reward and is implicated in
conditions such as drug addiction and eating disorders.
Dopamine is the primary neurotransmitter involved in the
brain reward pathways [127] and in the reward value of
sweet taste, mainly because sweet taste activates meso-
limbic DA circuits involved in the mediation of natural as
well as drug rewards. Mice lacking the cellular machinery
required for sweet taste transduction (trpm5-/-) learned to
prefer the postingestive effects of sucrose. These mice did
not develop a preference for sucrose per se probably due to
the short training sessions [128]. However, Zuckerman
et al. [129] reported that trpm5 KO mice learned to prefer
glucose but not fructose solutions in 24-h two-bottle choice
tests. Furthermore, trpm5 KO mice developed a robust
preference for sucrose solutions based solely on caloric
content. Sucrose intake induced DA release and increased
neuronal responses in the ventral striatum of these mice in
the absence of gustatory input. These findings suggested
that calorie-rich nutrients could directly influence brain
reward circuits that control food intake independently of
palatability or functional taste transduction [128]. Dopa-
mine release is stimulated in the NAc by the sweet taste in
the mouth. [130] It was reported that the neurochemical
effects observed with intermittent sugar access are not only
due to sucrose postingestive properties but also to the sweet
taste of sucrose [130].
The mesolimbic DA projection from the ventral teg-
mental area (VTA) to the NAc is frequently implicated in
reinforcement functions [127]. Data from animal models of
binge-eating but with normal weight show that behavioural
and neuronal consequences of bingeing on a palatable food
are different from those that result from simply consuming
the palatable food in a non-binge manner, i.e. physiologi-
cal, neural, and behavioural effects independent of a DIO
[131]. Excessive intake of palatable foods under specific
conditions can produce behaviours and changes in the brain
that resemble an addiction-like state, such as greater acti-
vation of the anterior cingulate cortex, the medial orbito-
frontal cortex, and the amygdala, regions associated with
motivation. These changes may be more closely correlated
with binge-eating behaviour than they are to body weight
[131].
It was recently suggested that people at risk of obesity
initially show a hyperfunctioning in the gustatory and
somatosensory cortices that increases pleasure perception
from food, leading to increased reward, overeating, and
weight gain. This overeating may induce receptor down-
regulation in the striatum, increasing the likelihood of
further overeating and continued weight gain. Obese versus
lean humans show less activation in the dorsolateral pre-
frontal cortex, and greater activation of regions involved in
the reward value of stimuli (striatum, amygdala, orbito-
frontal cortex, and mid-insula), in attention regions (ventral
lateral prefrontal cortex), and in somatosensory regions, in
response to high-fat/high-sugar food images relative to
control images [132]. Similarly, DIO minipigs showed
deactivations in the dorsolateral and anterior prefrontal
cortices and activations in the ventral posterior nucleus of
the thalamus and middle temporal gyrus, compared to lean
minipigs. Moreover, the anterior and dorsolateral pre-
frontal cortices as well as the insular cortex activity were
negatively associated with body weight. These data sug-
gested that the reduced activation of the prefrontal cortex
observed in obese subjects is an acquired feature of obesity
[22].
McCutcheon et al. [133] showed that DA release in the
NAc core to food-predictive cues is strongly modulated by
food’s characteristics. Cues paired with sucrose (the pre-
ferred reward) evoked greater DA release, than cues pre-
dicting saccharin (the non-preferred reward). This
subjective preference and greater DA release could result
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from a difference in the orosensory qualities of the pellets
or an aversion to the bitter taste of saccharin, and suggests
that sucrose may more powerfully motivate behaviour
[133].
The NAc, the amygdala, and the medial prefrontal
cortex are implicated as central sites of action for the
suppressive effects of the DA-1 receptor (D1R) and DA-2
receptor (D2R) antagonists (SCH23390 and raclopride,
respectively), on sugar intake and on the expression of
flavour preferences conditioned by the sweet taste of sug-
ars. Subcutaneous administration of D1R agonist prior to
food preference test reduced the intake of the regular diet
and induced a strong preference for high-fat/high-sucrose
food, whereas D2/D3 receptor agonist had the opposite
effects. These results suggested that the DA receptor
subtype is a major determining factor of the direction in
which sweet food preference is modulated, in addition to
the level of DA release in the NAc [134]. Subcutaneous
injections of D1R and D2R antagonists substantially and
dose dependently reduced the intake and preference of
sucrose solutions but not saccharin solutions, suggesting
that the antagonists decreased the reinforcing value of
sucrose, but not saccharin, solution [135]. Systemic
administration of dopamine D1R (SCH23390) and D2R
(raclopride) antagonists in the medial prefrontal cortex and
amygdala, but not in the NAc shell, blocked the acquisition
and expression of fructose-conditioned flavour preferences
in rats [136].
In contrast to the effect of intragastric glucose following
bilateral injection of the D1R antagonist on blocking the
Fig. 2 Hypothetical model of the peripheral and central effects of
glucose on food intake. Luminal glucose activates vagal afferents via
the release of 5-HT or GLP-1. Vagal afferents express GLP-1 and
5-HT receptors, and are implicated in the regulation of insulin
secretion. Many neuronal signals are communicated via the vagus
nerve to the brain stem, which relays the glucose signal to
hypothalamic nuclei and then to the pertinent target cells: NPY/
AgRP and POMC/CART neurons. NPY neuropeptide Y, AgRP
agouti-related protein, POMC proopiomelanocortin, CART cocaine–
amphetamine-related transcript, AMP adenosine monophosphate,
AMPK AMP kinase, ACC acetyl-CoA carboxylase. Black arrows
activation; discontinued red lines inhibition; thin discontinued red
line weak activation [4, 51, 52, 54, 57, 58, 72, 182]
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acquisition of conditioned flavour preferences [137],
bilateral hypothalamic injections of D1R and D2R antag-
onists failed to alter the acquisition of fructose-conditioned
flavour preference in rats [138]. These findings suggest an
important difference between flavour–flavour and flavour–
nutrient-conditioned flavour preferences. Fructose intake
and fructose-conditioned flavour preference appear to be
more dependent on D2R activity than sucrose intake.
Injections of D1R antagonist into the amygdala or NAc
during training did not block fructose conditioning, but did
block the acquisition of a flavour preference produced by
glucose infusions [139]. Rats under a high-fat diet
responded to all raclopride doses with reductions in sucrose
intake, but not in fructose intake, while rats fed a high-fat
and sugar diet only responded to the highest dose of ra-
clopride, with significant reductions in fructose intake
[140]. These data indicate that there is a differential
involvement of D1R and D2R in flavour–flavour and fla-
vour–nutrient preference, respectively. An explanation may
include differential neural and hormonal postingestive
effects exerted by fructose and sucrose. In this context, it
may be possible that the high-fat diet and the high-fat and
high-sugar diet altered sucrose and fructose preferences
differently as a result of their differential effects on oral
and gastrointestinal signals upstream the reward system
[140].
Fig. 3 Hypothetical model of the peripheral and central effects of
fructose on food intake. Luminal fructose induces weak release of
5-HT and GLP-1 from enteroendocrine and L cells, respectively,
weak PYY, insulin and leptin secretion, as well as weak ghrelin
suppression. Many neuronal signals are communicated via the vagus
nerve to the brain stem, which relays the glucose signal to
hypothalamic nuclei and then to the pertinent target cells: NPY/
AgRP and POMC/CART neurons. NPY neuropeptide Y, AgRP
agouti-related protein, POMC proopiomelanocortin, CART cocaine–
amphetamine-related transcript, AMP adenosine monophosphate,
AMPK AMP kinase, ACC acetyl-CoA carboxylase. Black arrows
activation; discontinued red lines inhibition; grey arrows low
secretion or low activation [4, 37, 51, 52, 54, 58, 59, 72, 182]
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Interactions between peripheral signals
and the mesolimbic dopamine system
Anatomical and functional evidence demonstrates multi-
ple interactions between the mesolimbic DA system and
peripheral signals regulating food intake. One such system
is the CCK system. In an obese rat model lacking the
CCK-1 receptors (Oletf), treatment with D2R antagonist
raclopride, but not D1R antagonist SCH23390, showed
increased potency to reduce sucrose real intake, indicating
that D2R are involved in heightened increased con-
sumption of sucrose observed in these obese rats. These
findings confirm the notion that DA increases sucrose
intake due to the assignment of an actual rewarding value
of sucrose primarily based on its sensory stimulatory
effects. They also confirm that altered DA signalling
present in obesity is involved in the increased potency of
sucrose palatability to maintain ingestion in obese sub-
jects [141].
Ghrelin has recently emerged as a potent modulator of
the mesolimbic dopaminergic reward pathway, suggest-
ing a role for ghrelin in food reward. Ghrelin targets a
key mesolimbic circuit involved in food and drug-
induced reinforcement, i.e. DA projection from the VTA
to the NAc [142]. Skibicka et al. [143] identified the
VTA, a key structure in the mesolimbic reward system,
as a primary target for ghrelin’s effects to increase
motivation for a sweet food reward. Peripherally and
centrally administered ghrelin significantly increased
operant responding and incentive motivation for sucrose.
Conversely, blockade of GHS-R1A (Ghrelin type 1A
receptor) signalling significantly decreased operant
responding for sucrose. These findings indicate that
ghrelin plays an important role in motivation and rein-
forcement for sucrose. They suggest that ghrelin antag-
onists have therapeutic potential for the treatment for
obesity and for suppressing sweet food overconsumption
[143, 144].
Lustig [35] reviewed that chronic hyperinsulinemia
may prevent DA clearance from the NAc and leptin
signalling, leading to leptin resistance and increased food
intake. Thus, by promoting insulin resistance and hyper-
insulinemia, fructose excessive intake may alter DA
neurotransmission and the hedonic response to food
leading to overeating [35]. Increasing the palatability of
food by the addition of sucrose undermines normal satiety
signals and motivates energy intake independent of
energy needs [145]. Animal models of intermittent sugar
administration can induce behavioural alterations consis-
tent with dependence, i.e. bingeing, withdrawal and anx-
iety, craving, and cross-sensitisation to other drugs of
abuse [146].
Dietary sugars and the endocannabinoid system
The endocannabinoid system is a lipid-signalling system
composed of three non-ubiquitous receptors (CB1, CB2,
and likely CB3 receptor), two endogenous ligands (i.e.
anandamide and 2-arachidonoyl-glycerol, 2-AG), and the
enzymatic machinery for their synthesis and degradation
[147]. This system is implicated in the regulation of
appetite, eating behaviour, and body weight homeostasis at
both peripheral and central levels. In the brain, the endo-
cannabinoid system appears to control food intake mainly
at three functional levels, i.e. the hypothalamus, the dorsal
vagal complex, and the limbic system, by affecting satiety
signals and interacting with brain reward pathways [148,
149]. Previous studies have revealed the ability of mari-
juana, or of its main psychoactive component D9-tetra-
hydrocannabinoid (D9-THC), to induce not only
hyperphagia, but also to increase the desire to consume
highly palatable food and to impact food selection con-
comitantly [150].
Endocannabinoids have been implicated in the regula-
tion of consumption of palatable food, sugar in particular.
CB1 receptor antagonist (SR 141716, also known as Ri-
monabant, an anorectic anti-obesity drug) resulted in
reduced body weight and appetite for sweet foods and
drinks [151]. Following low oral doses of D9-THC (0.25
and 0.40 mg/kg), there was a dose-dependent increase in
preference for palatable food and sucrose intake in rats.
Similarly, administration of D9-THC (0.5, 1.0, and 3.0 mg/
kg), anandamide (1.0 and 3.0 mg/kg), and 2-AG (0.2, 1.0,
and 2.0 mg/kg) substantially increased the number of licks
of 10 % sucrose solution, due to increased bout duration
rather than bout number, whereas administration of CB1
antagonist SR141716 significantly decreased total licks
[152]. Rimonabant also specifically reduced sucrose,
alcohol, and sweet food intake in rats and marmosets [148].
Endocannabinoids (anandamide and 2-AG) peripherally
administered selectively enhanced gustatory nerve (chorda
tympani) responses and electrophysiological responses of
taste cells, located on the anterior tongue innervated by the
chorda tympani nerve, to sweeteners (i.e. saccharin, glu-
cose, and sucrose) in mice. These sweet-enhancing effects
of endocannabinoids were mediated by CB1 receptors,
which were coexpressed in taste cells with the sweet
receptor subunit T1R3 in taste cells. Indeed, endocannab-
inoid administration also increased T1R3 taste cells
responses to sweeteners [153]. These effects remain to be
explored with fructose stimulation. However, since no
differences were previously found in gustatory nerve
(chorda tympani) responses to glucose, sucrose, and fruc-
tose in pigs [154], one might speculate that endocannabi-
noids may exert similar degree of taste enhancement
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sensitivities between these three sugars. But this hypothesis
remains unclear since neural responses do not always
predict functional sensitivity; moreover, the observed
responses do differ at various stimulus concentrations, and
it is unclear how endocannabinoids would interact with
this. Intraperitoneal administration of endocannabinoids to
wild-type mice selectively enhanced gustatory nerve
responses and electrophysiological responses of taste cells,
located on the anterior tongue innervated by the chorda
tympani nerve, to sweet compounds (sucrose, saccharin,
and glucose). These sweet-enhancing effects of endocan-
nabinoids were mediated by CB1 receptors, which are
coexpressed in taste cells with the sweet receptor compo-
nent T1R3 [153].
Consumption of fructose solution in combination with
standard rat chow resulted in increased mRNA levels of
CB1 in the rat hypothalamus [7]. Intake of sucrose, glu-
cose, and fructose solutions during 7 days affected the
mRNA expression of the majority of enzymes involved in
the synthesis and degradation of anandamide and 2-AG, in
rats [10]. Fructose solution increased mRNA levels of fatty
acid amide hydrolase (FAAH) (involved in anandamide
degradation), compared to water, glucose, and sucrose
solutions. This suggests that fructose intake might induce
an overproduction of anandamide and that an up-regulation
of this enzyme is necessary to maintain normal levels of
anandamide. The three sugar solutions induced a down-
regulation of phospholipase C (involved in anandamide
synthesis). This may suggest an attempt to maintain
anandamide at physiological levels during periods of high-
sugar consumption irrespective of the nature of the sugar.
Monoglyceride lipase (MGLL), the main enzyme involved
in 2-AG degradation, was also down-regulated by the three
sugar solutions compared to water intake. This would
suggest that 2-AG is degraded less readily in rats drinking
sugar solutions than in water drinking rats. However, only
fructose intake increased mRNA levels of diacylglycerol
lipase 1b (involved in 2-AG synthesis), suggesting that
more 2-AG is being produced [10]. However, the inter-
pretation of these results is conflicting, given the simulta-
neous increase or decrease in enzymes involved in the
synthesis and degradation of endocannabinnoids, respec-
tively, induced by the sugar solutions. Besides, neither
protein levels nor actual concentrations of endocannabi-
noids were measured, making it difficult to draw a con-
clusion. Further studies are needed to understand the
implications of these results. Cani et al. [155] demonstrated
that a diet-induced obesity (DIO) by excess dietary lipid
intake is associated with altered expression of CB1 mRNA,
higher plasma endocannabinoids, or increased adipose
tissue endocannabinoid synthesis. Blockade of CB1
receptor improves the gut barrier and reduces metabolic
endotoxemia, by a mechanism independent of eating
behaviour, suggesting a control of gut permeability by CB1
receptors through interactions with gut microbiota [155]. It
is possible that fructose could also modulate the intestinal
endocannabinoid system by a similar mechanism, but
future studies are needed to investigate this hypothesis.
Finally, endocannabinoids have been proven to interact
with brain reward pathways in a manner similar to other
reward-enhancing drugs. Therefore, the endocannabinoid
system might affect eating behaviour through the modu-
lation of the reward circuit [148]. Which are the effects of
the different dietary sugars on the endocannabinoid system
and their interaction with brain reward pathways to affect
eating behaviour is a question that remains incompletely
understood and needs further investigation. As presented in
the previous section on the DA system, different types of
sugars differentially modulate this system. Therefore, it is
possible that these differences might also be observed in
the endocannabinoid system and this requires further
investigation.
Dietary sugars and the opioid system
Opiodergic neurotransmission within the brain reward
circuit mediates hedonic aspects of sweet-palatable foods
[8]. Chronic suppression of the endogenous l-opioid
receptor signalling in the nucleus accumbens (NAc) shell
and core significantly attenuates the development of a DIO
by reducing the intake of palatable, high-sugar foods in rats
[156]. Opioid antagonism in the NAc is associated with a
reduction in sweet food preference and sucrose intake, and
weakens hedonic properties of sucrose and motivation for
sucrose [156–158]. The latter (‘wanting’) may be attrib-
utable to the decrease in ‘liking’ (hedonic properties) [158].
Conversely, stimulation of l-opioid signalling in the NAc
increases sucrose intake and motivation [159].
The consumption of sweet tastants results in neuro-
chemical changes within the brain, which may reflect a
shift in opioid-mediated responses. Sucrose and glucose
intake paired with opioid receptor antagonism (naloxone)
induced an increase in the number of c-Fos-positive
nuclear profiles [160] and an elevation in opioid l-1
receptor binding in the cingulate cortex, hippocampus,
locus coeruleus, and accumbens shell, associated with the
presence of opiate withdrawal-like symptoms, such as teeth
chattering [161]. These results suggest that ingestion of
sucrose and glucose induces neurochemical changes within
the opioid brain circuitry. Opioids support a drive to con-
sume sugar, and this mechanism is mainly dependent on
their ability to act through the reward system. Similar to the
reports in the cocaine studies for drug euphoria and crav-
ing, sweet liking may increase with the dose while sweet
wanting may not [162].
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Overall, opioid signalling, particularly through its
l-receptor in the NAc, is involved in the expression of
reward behaviours induced by the consumption of sweet-
palatable foods and may be involved in the development of
DIO. However, the vast majority of these studies, in both
animals and humans, regarding opioids and sugar intake
have used sucrose as the source of sugar. One of the few
studies using both glucose and fructose was performed by
Bernal et al. [163]. They found that rats develop strong
preferences for flavours paired with the sweet taste of
fructose or the post-oral nutrient effects of glucose. Opioid
antagonism at the NAc shell and core did not block sugar-
conditioned flavour preference at any dose and with neither
glucose nor fructose solutions [163]. However, the authors
did not directly compared to glucose versus fructose
stimulus so there is no clear evidence about possible dif-
ferences between these sugars following opioid antagonism
in the NAc. Given the high amounts of fructose currently
consumed in Western diets, it would be interesting to
directly compare the effects of free fructose and glucose to
those observed with sucrose on the opioid system. Given
the observations of the effects of fructose intake on appe-
tite, its higher palatability compared to glucose, and its
differential effects at both peripheral and central levels,
including the DA system, one might speculate that fructose
could induce more profound effects on this system than
sucrose or glucose. However, since fructose may not cross
the BBB at typical intake levels, this hypothesis seems
unrealistic. Further research directly comparing the effects
of sucrose, glucose, and fructose is needed to investigate
this hypothesis.
Controversial findings
Several pieces of evidence have led to the assumption that
fructose excessive intake may be responsible for the
increasing prevalence of obesity since the last decades.
This has stimulated research aiming at understanding the
underlying mechanisms of this fructose-induced obesity.
For example, epidemiologic and experimental evidence
indicates that a greater consumption of sugar-sweetened
beverages with HFCS is, in fact, associated with weight
gain and obesity, and that HFCS accounts for 40 % of
caloric sweeteners used in the United States [13, 16, 17,
164, 165]. In addition to these epidemiological data, evi-
dence has shown that fructose induces smaller increases in
insulin, leptin, and other satiety peptides compared to
glucose [37, 55–59]. This suggested an endocrine mecha-
nism by which fructose might induce greater food intake
and weight gain than glucose. However, while it is true that
fructose intake in the form of HFCS makes up a significant
proportion of energy intake in the Western diet [13, 164], it
is also true that this increase in fructose intake is neces-
sarily associated with an increase in total energy intake and
in glucose (from HFCS). Besides, equal amounts of glu-
cose and fructose are necessary for maximal fructose
absorption in humans [166]. This makes questionable the
effect of fructose per se for increasing food intake,
inducing weight gain and metabolic diseases [16]. In fact,
there are some well-controlled studies showing divergent
findings in this regard that are important to discuss here
given the extended great concern regarding the fructose-
induced obesity.
Lindqvist et al. [7] found no differences in terms of food
intake, PYY, and leptin serum levels following 2-week
intake of sucrose, glucose, or fructose solutions in rats.
Moreover, these authors found that the fructose-drinking
group had the smallest increase in food intake, probably
attributed to the lowest intake of fructose solution. This
was attributed to the fact that fructose is sweeter than
sucrose and glucose [7], and it may also be attributable to
the short period (2 weeks) of sugar solution intake. In
addition, no difference was found in energy intake and
weight gain following 50-day intake of sucrose, glucose, or
fructose solutions, but body adiposity increase was greater
with sucrose than with fructose solutions [70]. In humans,
no differences in terms of energy intake, satiety, and
energy compensation, nor in plasma glucose, GLP-1,
insulin, and ghrelin release were found following acute
ingestion of preload drinks containing sucrose or HFCS
(1.5 MJ) [167]. This lack of difference in satiety was found
despite different biochemical properties (leading to dif-
ferent transport across the gut epithelium and thus different
transit time) as well as different mechanisms underlying
satiety between sucrose- and HFCS-containing drinks [64,
110, 168]. Therefore, more studies are needed to clarify
these discrepancies.
Glendinning et al. [169] investigated in four strains of
mice given free access to sugar solutions and showed that
sucrose promoted more overeating, resulting in increased
weight gain and adiposity compared to fructose, regardless
of mouse strain. Moreover, all strains licked more avidly
the sucrose than the fructose solutions. These authors
reported as well that mice and rats consume less fructose
than isocaloric sucrose [169]. Fructose orally ingested or
intraduodenally infused induced insulin release and inhib-
ited food intake more than glucose in rats and humans [7,
170, 171], whereas another study found no difference
between these sugars orally ingested on food intake [172].
Sclafani and Ackroff [173] reported that 16 % glucose
intragastric infusion condition a strong flavour preference
in mice, whereas fructose and galactose infusions failed to
do so. The latter findings are opposed to other findings,
suggesting that fructose is a weaker elicitor of satiation
signals [54, 62] and may have a more rewarding effect
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probably due to its higher sweetness than glucose [174].
The only rodent study that appears in the literature
reporting fructose-induced weight gain more than sucrose-
fed mice used a 15 % fructose solution or a 10 % sucrose
solution, which invalidates the findings [67]. White [175]
recently reviewed that many animal studies have used
extremely high-fructose doses, or altered the usual glucose-
to-fructose ratio that are not predictive of typical human
diets, leading to abnormal metabolism. He exposed as well
that (i) the increased energy intake per capita coupled with
insufficient compensating exercise is a more consistent
explanation to the obesity epidemics; (ii) there has been no
positive correlation between fructose intake and increasing
rates of obesity; (iii) consumption of added sugars has not
increased, but actually decreased for more than a decade;
and (iv) all sources of fructose in human diets contain
comparable amounts of glucose, and glucose is the domi-
nant sugar in the human diet (5 times more glucose than
fructose). Besides, fructose is rapidly metabolised in the
liver to glucose. The fructose hypothesis is refuted by
studies using real-world fructose exposures showing no
differential effects versus control, and cause-and-effect
evidence of adverse effects is lacking at typical human
exposure levels and patterns [175]. Sun et al. [176] ana-
lysed the intake patterns of [ 25,000 subjects in the
NHANES 1999–2006 databases and found that daily
fructose intakes with the American diet averaged 9 % of
daily intake, that fructose is rarely consumed solely or in
excess over non-fructose sugars, and that fructose and non-
fructose sugar ordinary intake was not positively associated
with indicators of metabolic syndrome, uric acid, or BMI.
A metaanalysis by Sievenpiper et al. [177] reported the
effects of fructose on body weight in controlled feeding
trials. They found that fructose has no effect on body
weight in isocaloric trials (637 participants) compared to
isocaloric diets containing a non-fructose sugar. In con-
trast, high doses of fructose in hypercaloric trials (119
participants) induced weight gain. The effect of fructose-
induced body weight gain in hypercaloric trials may have
been due to excess energy intake rather than fructose itself
because (i) weight gain is similar to that which would be
predicted with consumption of a 2,000-kcal diet with
similar amount excess energy; (ii) high-precision estimates
of energy expenditure, fat, and carbohydrate oxidation
using whole-body calorimetry showed no differences
among fructose, glucose, or sucrose [178]. Taken together,
these data suggest that an excess energy may be a more
important factor for weight gain than the type of sugar.
Concerning some of the central effects, both oral intake
of glucose and fructose solutions during 2 weeks produced
a down-regulation of POMC mRNA levels [7]. Processing
of POMC by pro-hormone convertases results in the
production of a-MSH, which suppresses feeding, and
ß-endorphin, which stimulates it. Thus, POMC mRNA
decrease, together with a decrease in ß-endorphin, may
indicate the down-regulation of a potent suppressor of food
intake and less rewarding signals through the opioid
pathway by sugar solutions. mRNA levels of NPY were
also reduced by the consumption of both sugar solutions.
NPY is a potent stimulator of feeding, especially sugar
intake. Thus, the observed reduction in NPY mRNA levels
in this study may attempt to balance for calorie overcon-
sumption. Despite the down-regulation of hypothalamic
NPY and POMC mRNA, there was no reduction in
hyperphagia induced by the consumption of sugar solutions
[7].
Taken together, the ‘fructose hypothesis’ remains con-
troversial, and a cause-and-effect association between
fructose intake and the metabolic syndrome and obesity has
not been clearly confirmed yet. Thus, there is a need for
more research on fructose with experimental designs based
on physiological conditions so that a consensus could be
established.
Conclusions and perspectives
The aim of this review was to critically discuss the effects
of dietary sugars at both central and peripheral levels.
Based on the current findings, diverse hypotheses were
postulated all along the review sections with two main
goals: (i) to open new perspectives for future research that
may contribute to our understanding of current data with a
special focus on fructose, and (ii) to clarify controversial
findings in order to advance in the establishment of a
consensus concerning the differential effects of the main
dietary sugars found in humans diets at both peripheral and
central levels.
In summary, the reports presented here suggest differ-
ential effects of glucose and fructose at multiple levels.
Contrary to glucose, excessive fructose intake may provoke
metabolic disturbances, such as an increased gut perme-
ability, low-grade inflammation, NAFLD, insulin resis-
tance, and dyslipidaemia. Through luminal gut detection
and following the activation of sweet taste receptors, glu-
cose triggers the secretion of peripheral anorexigenic
peptides, i.e. insulin, leptin, GLP-1, PYY, and suppression
of orexigenic peptides (e.g. ghrelin) that activate vagal
pathways and act on brain target regions controlling
appetite (e.g. the arcuate nucleus of the hypothalamus and
the dorsal vagal complex), thus leading to appetite sup-
pression and reward response. Glucose may also directly
induce its effects on appetite suppression by crossing the
BBB, where it suppresses AMPK activity, an effect that
stimulates neuronal activity of POMC/CART expressing
neurons, which contributes as well in the satiety response.
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Fructose may have different effects on the secretory profile
of appetite peptides and neuropeptides, leading to reduced
appetite suppression as well as an indirect effect on the
reward response, i.e. through a deficient stimulation of
leptin and insulin secretion, hormones implicated in the
rewarding effects of palatable food, fructose may provoke a
deficient reward response leading to overeating. However,
most of these results were obtained from rodents and using
extremely high doses of fructose far from the typical
human diets. Other studies found small or no differences
between glucose, sucrose, and fructose in appetite peptide
secretion, food intake, and weight gain. These discrepan-
cies may be due to differences in species, metabolic phe-
notype, experimental approaches, form of administration
(peripheral or central infusions), in the form of solutions or
added in the diet, doses, duration of exposure, and exper-
imental diet compositions. These differences make difficult
to interpret and find a definite conclusion on these effects.
Several clues and hypothesis were proposed for future
research aiming at clarifying these controversial findings.
Besides, fructose is rarely consumed isolated in the diet,
but rather in the form of HFCS or sucrose, or consumed
along with glucose. In fact, luminal glucose enhances
fructose absorption. Therefore, no definite conclusions
could be established for giving any nutritional recom-
mendations to suppress or reduce fructose from the human
diets. Overall, data obtained from well-controlled studies in
pigs or rodents, and epidemiological studies in humans,
suggest that it is the association between fructose and other
components in the diet, such as fat, cholesterol, and other
dietary sugars, as well as total caloric intake coming from
dietary sugars, responsible for the metabolic effects and
weight gain, rather than fructose intake per se. Given the
difficulty to perform controlled studies in humans for eth-
ical reasons, a valuable approach may be through the use of
the pig model that has been shown to present greater
similarities to humans than smaller animals (e.g. cats and
rodents).
At the central level, consistent evidence has suggested
the capacity of fructose to induce changes in neuropeptides
or brain activity, with a resulting decrease in the satiety
response. However, there is no clear evidence of the
capacity of fructose orally ingested to cross the BBB. Thus,
it seems unlikely that fructose could directly induce
changes in brain appetite peptides to produce its effects on
satiety. Fructose is partially (12 %) metabolised in the gut
during absorption, and the liver and kidneys rapidly me-
tabolise the remaining fraction. This leads to very low
fructose plasma concentrations and during a very short
time, as well as the low GLUT5 affinity for fructose and
low GLUT5 concentrations in the BBB, and the possibility
of a fructose malabsorption when ingested in high doses.
These factors make unlikely that fructose could cross the
BBB and induce significant effects on the brain. Contrary
to the well-established direct central effects of glucose on
energy homeostasis and food intake through central glu-
cose-sensing mechanisms, the fructose effects on eating
behaviour are more likely to be exclusively through indi-
rect mechanisms, i.e. via activation of T1R2/T1R3-sensing
mechanism in the mouth and gut, as well as intestinal
glucose transporters. This activation triggers the secretion
of appetite peptides that may affect thereafter brain neu-
ropeptides involved in appetite control, as well as the
activation or deactivation of brain regions involved in
appetite and reward. Therefore, fructose may indirectly
influence appetite and reward through changes in the levels
of peripheral neural input or metabolic intermediaries
modifying the activation of brain regions implicated in
appetite and reward. While fructose effects on the reward
circuitry seem to be consistent when administered i.c.v. or
intragastrically, more studies are needed to confirm these
effects following fructose orally ingested.
This review presented consistent evidence showing the
implication of the endocannabinoid, opioid, and mesolim-
bic dopaminergic systems in the modulation of sweet taste
reward and in the development of preferences for sweet
taste that may lead to aberrant eating behaviours. This
addictive-like condition could be explained by a desensi-
tisation of the reward pathways. However, most of these
studies used sucrose as the source of sugar in the experi-
ments, thus making it impossible to separate the specific
effects of glucose and fructose or their interaction. The
apparent parallel increases between fructose intake and
obesity development make necessary more research to
elucidate possible differences between glucose, sucrose,
and fructose on the reward circuitry. There may be a
relationship between satiety signals and reward signals. For
example, the satiety hormones insulin and leptin are
implicated in the reward effect from palatable food. In this
regard, a hypothesis was postulated arguing that if fructose
induces lower leptin and insulin secretions, it may also
induce less satiety effect and a less rewarding effect
compared to glucose intake, and therefore an increase in
food intake to compensate for this lack of reward from
food. If this were true, then fructose would be more
addictive than glucose. However, the opposite may also be
plausible: if fructose is less rewarding than glucose, it may
not stimulate excessive intake, as is the case of several
studies reported in the ‘Controversial findings’ Section.
Therefore, these hypotheses should be further explored.
This may be another angle for weighing detrimental effects
of sugars and thus should be investigated in future studies.
We presented results showing that sucrose intake indu-
ces DA release and increases neuronal activity in the brain
reward circuitry. Dopamine release is stimulated in the
NAc by the sweet taste in the mouth and by the
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postingestive actions of sugars. Considering that fructose is
sweeter than glucose and sucrose for humans, one might
hypothesise that fructose could induce greater DA release
compared to glucose and sucrose, which may lead to
increased reward from food, increased food intake, and
aberrant eating behaviours. However, this hypothesis
remains controversial since calorie-rich nutrients (i.e.
sucrose) can directly influence brain reward circuits that
control food intake independently of palatability or func-
tional sweet taste transduction. On the other hand, most of
the studies comparing the effects of intermittent and/or
excessive sugar intake with the effects of addiction to drugs
on the dopamine system have used sucrose as well, and
very few have used glucose; to our knowledge, none has
compared fructose versus glucose on the characteristics of
addiction (e.g. escalation of intake [179]). It was until
recent years that researchers began to compare the effects
of DA receptor antagonists on the expression of fructose-
conditioned preferences compared with sucrose. These
studies have mainly found that ‘fructose intake and fruc-
tose-conditioned flavour preference appear to be more
dependent on D2R activity than sucrose intake’ (e.g. [136,
138, 139]). However, the physiological implications of
these results still remain to be clarified. Therefore, future
studies should directly compare DA release levels, DA
transporter expression and DA receptor expression patterns
following ingestion of glucose, sucrose, and fructose.
Concomitantly, these studies should also measure appetite
peptide secretion levels, neuropeptides, brain activity of
regions implicated in appetite and reward, and feeding
behaviour tests (e.g. food choice, eating microstructure,
operant conditioning, and progressive ratio). This inte-
grated approach may clarify the possible links between
satiety and reward effects induced by the ingestion of
different dietary sugars. While some recent evidence exists
showing a differential effect between glucose and fructose
on the function of brain regions implicated in appetite and
food reward, this concept needs to be confirmed in humans
and a non-rodent animal, under controlled experimental
conditions and using a physiological fructose intake. An
additional question that should be addressed in future
studies is which are the underlying mechanisms leading to
fructose effects on brain functions, considering that this
sugar might not be able to cross the BBB and directly
produce these observed effects. In this regard, several
hypotheses were presented here that may contribute to
address this question in future studies.
Future research should therefore focus on resolving the
apparently inconsistent findings, suggesting that excessive
fructose intake may promote adverse effects at both
peripheral and central levels to a greater extent than those
provoked by glucose or sucrose. There is a particular need
to integrate the metabolic, behavioural, and neurological
effects of these sugars. An approach combining behav-
ioural (e.g. progressive ratio) and metabolic (e.g. plasma
and protein levels of peptides and neuropeptides) mea-
surements, PET, and fMRI imaging, together with the use
of an animal model closer to humans (i.e. the pig), would
contribute to an improved understanding of the complexity
of the development of diseases induced by dietary sugars.
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